Your browser doesn't support javascript.
A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.
Ryan, Feargal J; Norton, Todd S; McCafferty, Conor; Blake, Stephen J; Stevens, Natalie E; James, Jane; Eden, Georgina L; Tee, Yee C; Benson, Saoirse C; Masavuli, Makutiro G; Yeow, Arthur E L; Abayasingam, Arunasingam; Agapiou, David; Stevens, Hannah; Zecha, Jana; Messina, Nicole L; Curtis, Nigel; Ignjatovic, Vera; Monagle, Paul; Tran, Huyen; McFadyen, James D; Bull, Rowena A; Grubor-Bauk, Branka; Lynn, Miriam A; Botten, Rochelle; Barry, Simone E; Lynn, David J.
  • Ryan FJ; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Norton TS; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
  • McCafferty C; Haematology Research, Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Blake SJ; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Stevens NE; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • James J; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
  • Eden GL; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
  • Tee YC; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Benson SC; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Masavuli MG; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia.
  • Yeow AEL; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia.
  • Abayasingam A; School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW 2052, Australia; The Kirby Institute, Sydney, NSW 2052, Australia.
  • Agapiou D; The Kirby Institute, Sydney, NSW 2052, Australia.
  • Stevens H; Clinical Haematology Department, Alfred Hospital, Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3800, Australia.
  • Zecha J; Dynamic Omics, Centre for Genomics Research, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
  • Messina NL; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia; Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
  • Curtis N; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia; Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
  • Ignjatovic V; Haematology Research, Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Monagle P; Haematology Research, Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Tran H; Clinical Haematology Department, Alfred Hospital, Melbourne, VIC 3004, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, VIC 3800, Australia.
  • McFadyen JD; Clinical Haematology Department, Alfred Hospital, Melbourne, VIC 3004, Australia; Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia; Baker Department of Cardiometabolic Health, The University of Melbourne, Parkville, VIC 3010, Australia
  • Bull RA; School of Medical Sciences, Faculty of Medicine, UNSW, Sydney, NSW 2052, Australia; The Kirby Institute, Sydney, NSW 2052, Australia.
  • Grubor-Bauk B; Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia.
  • Lynn MA; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.
  • Botten R; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia.
  • Barry SE; Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
  • Lynn DJ; Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia. Electronic address: david.lynn@sahmri.com.
Cell Rep Med ; 4(3): 100971, 2023 03 21.
Статья в английский | MEDLINE | ID: covidwho-2244756
ABSTRACT
Identifying the molecular mechanisms that promote optimal immune responses to coronavirus disease 2019 (COVID-19) vaccination is critical for future rational vaccine design. Here, we longitudinally profile innate and adaptive immune responses in 102 adults after the first, second, and third doses of mRNA or adenovirus-vectored COVID-19 vaccines. Using a multi-omics approach, we identify key differences in the immune responses induced by ChAdOx1-S and BNT162b2 that correlate with antigen-specific antibody and T cell responses or vaccine reactogenicity. Unexpectedly, we observe that vaccination with ChAdOx1-S, but not BNT162b2, induces an adenoviral vector-specific memory response after the first dose, which correlates with the expression of proteins with roles in thrombosis with potential implications for thrombosis with thrombocytopenia syndrome (TTS), a rare but serious adverse event linked to adenovirus-vectored vaccines. The COVID-19 Vaccine Immune Responses Study thus represents a major resource that can be used to understand the immunogenicity and reactogenicity of these COVID-19 vaccines.
Тема - темы
ключевые слова

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Vaccines / COVID-19 Vaccines / COVID-19 Темы: Вакцина Пределы темы: Взрослые / Люди Язык: английский Журнал: Cell Rep Med Год: 2023 Тип: Статья Аффилированная страна: J.xcrm.2023.100971

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Vaccines / COVID-19 Vaccines / COVID-19 Темы: Вакцина Пределы темы: Взрослые / Люди Язык: английский Журнал: Cell Rep Med Год: 2023 Тип: Статья Аффилированная страна: J.xcrm.2023.100971